Patients deserve affordable access to the best healthcare possible. That’s why Pfizer invests in research and development: to produce groundbreaking treatments, like the COVID-19 vaccine, that improve people’s lives. It’s this investment in innovation that enables our scientists to make dramatic strides in healthcare. Their work advances life-changing therapies for the millions of patients we serve.
To help even more patients access the medications they depend on, we need smart public policies that support both access and innovation. Americans deserve healthcare solutions that:
Pfizer is focused on increasing treatment options for patients through research and development as well as innovative, technically advanced manufacturing practices. We’re proud to be strengthening our capacity to develop and produce more advanced medicines that can help improve the lives of patients. As part of that effort, we recently announced a $450 million expansion of Pfizer’s largest manufacturing facility in Kalamazoo, Michigan.
Pfizer is focused on increasing treatment options for patients through research and development as well as innovative, technically advanced manufacturing practices. We’re proud to be strengthening our capacity to develop and produce more advanced medicines that can help improve the lives of patients. As part of that effort, we recently announced an $18 million expansion of Pfizer’s distribution center in Pleasant Prairie, Wisconsin.
Congress is considering passing a drug pricing policy that could threaten the future of groundbreaking cures! The policy would adopt similar policies that foreign countries use to restrict access to medicine.
There are major problems with this policy:
Making sure that medicines are accessible and affordable for patients is a goal we all share. But the dangerous policy outlined in H.R. 3 could threaten the future of groundbreaking cures.
Making sure that medicines are accessible and affordable for patients is a goal we all share. But policymakers are considering a dangerous Medicare reform policy that could threaten the future of groundbreaking cures.
Massachusetts state legislators are considering a dangerous bill that could stifle innovation, limit patients’ access to medicines, and interfere with market competition. The bill would grant the state government broad authority to arbitrarily set the prices of medications, which could threaten the biopharmaceutical industry’s contributions to the state’s economy.
We all share the goal of ensuring that life-saving medicines are accessible and affordable for all, but this misguided bill is not the solution. Massachusetts lawmakers should reject this proposal because it could: